EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Utilization of Model‐Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for Treatment of Sickle Cell Disease

Chay Ngee Lim, Nessy Tania, Satyaprakash Nayak iD, Denis Rybin, Jatin Narula, Steven Arkin

CPT: Pharmacometrics & Systems Pharmacology · 2026-04 · 15 (4)

DOI: 10.1002/psp4.70238 ↗

Kurz gefasst

Fallbericht in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 27.03.2026. Verfasst von Chay Ngee Lim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Drug Development, Hemoglobin, Sickle, Models, Biological. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Model‐informed drug development (MIDD) has an important role to play at various stages of drug development. In this case study, the application of MIDD in the early clinical development of a small‐molecule inhibitor of sickle hemoglobin (Hb) polymerization is highlighted. Starting from the setting of quantitative criteria, to using a combination of PKPD and semi‐mechanistic RBC modeling, and key biomarker analysis, based on data from a healthy participant first‐in‐human (FIH) study and historical data, we chart the strategic approaches planned and taken to inform decisions for the program, and the role of cross‐functional collaboration. Based on the projections from the PKPD and semi‐mechanistic RBC models, and key biomarker results from healthy participants, an informed decision was made to not proceed to a Phase 1b study in sickle cell disease (SCD) patients, underscoring the value of MIDD in early drug development decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellDrug DevelopmentHemoglobin, SickleModels, BiologicalAntisickling AgentsHumansBiomarkersErythrocytes

Stichwörter der Autor:innen

HbSMIDDsickle cell disease

Substanzen

Hemoglobin, SickleAntisickling AgentsBiomarkers

Autor:innen und Institutionen

  • Pfizer Inc, Cambridge, Massachusetts, USA.

ORCID-Profile: Satyaprakash Nayak

Zitieren

APA

Lim, C. N., Tania, N., Nayak, S., Rybin, D., Narula, J., & Arkin, S. (2026). Utilization of Model‐Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for Treatment of Sickle Cell Disease. CPT: Pharmacometrics & Systems Pharmacology, 15(4). https://doi.org/10.1002/psp4.70238

Vancouver

Lim CN, Tania N, Nayak S, Rybin D, Narula J, Arkin S. Utilization of Model‐Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for Treatment of Sickle Cell Disease. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(4). doi:10.1002/psp4.70238

BibTeX
@article{Lim2026,
  author = {Lim, Chay Ngee and Tania, Nessy and Nayak, Satyaprakash and Rybin, Denis and Narula, Jatin and Arkin, Steven},
  title = {Utilization of Model‐Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for Treatment of Sickle Cell Disease},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/psp4.70238}
}
Kostenlos starten →